← REGULATORY CHANGES
FEDERAL REGISTER · PROPOSED RULEMarch 18, 2026PROPOSED — NOT IN FORCE

Effective Date of Requirement for Premarket Approval Applications for Blood Irradiators Intended To Prevent Metastasis

What this record is not

Document details are published in the U.S. Federal Register; SPEQ surfaces them for reference and is not affiliated with or endorsed by the FDA or the Office of the Federal Register. The authoritative text is on federalregister.gov.

STATUSPROPOSED — NOT IN FORCE
PROPOSED EFFECTIVE—
COMMENTS CLOSEMay 18, 2026 · closed
APPLIES TO · SPEQ TAGBiologicsDevice
Document type
Proposed Rule
Agency
Health and Human Services Department
Published
March 18, 2026
Comments close
May 18, 2026
Document number
2026-05322
CFR references
21 CFR 892
Docket
FDA-2025-N-5995
ABSTRACT

The Food and Drug Administration (FDA) is proposing to require the filing of a premarket approval application (PMA) for blood irradiators intended to irradiate intraoperatively salvaged blood for cancer patients undergoing surgery to assist in prevention of metastasis, which are unclassified, preamendments devices. FDA is summarizing its proposed findings regarding the degree of risk of illness or injury designed to be eliminated or reduced by requiring the devices to meet PMA requirements of the Federal Food, Drug, and Cosmetic Act (FD&C Act) and the benefits to the public from use of the devices.

Abstract as published in the Federal Register.